Efficacy of Keishibukuryogan for Hot Flashes in Prostate Cancer Patients Receiving Androgen Deprivation Therapy: a Sub-analysis Focusing on Hormonal and Cytokine Levels

Overview

Journal Transl Androl Urol

Date 2023 Sep 8

PMID 37680217

Authors

Kazuyoshi Shigehara

Kouji Izumi

Kazufumi Nakashima

Shohei Kawaguchi

Takahiro Nohara

Yoshifumi Kadono

Atsushi Mizokami

Affiliations

Soon will be listed here.

Abstract

Background: The current study attempted to elucidate the mechanisms of keishibukuryogan (TJ-25) efficacy by focusing on hormonal and cytokine levels. This is a sub-analysis of serum hormonal and cytokine levels extracted from the single-arm prospective study.

Methods: Twenty-five participants were administrated TJ-25 at a dose of 2.5 g three times daily for 12 weeks, and competed for a diary of their hot flashes conditions. Various hormonal and cytokine values, including interleukin (IL)-8 and tumor necrosis factor-α (TNF-α), were measured at the baseline and 12-week visits. The correlation of hot flashes with hormonal and cytokine levels at baseline was investigated. As part of the responder analyses, all participants were divided into two groups based on the median baseline values of all hormones and cytokines at baseline, and the change amounts in strength and frequency of hot flashes from baseline to 12-week visits in both groups were compared. Furthermore, a correlation in change amounts (Δ values) by TJ-25 administration between hot flashes and each parameter was also conducted.

Results: Hot flashes intensity was inversely related to estradiol levels (r=-0.433, P=0.019), and frequency was inversely related to progesterone levels (r=-0.415, P=0.025). In the responder analyses, the effectiveness of TJ-25 for hot flash strength increased in the patients with higher levels of TNF-α at baseline (P=0.0372). TJ-25 was more efficient in frequency in the patients with higher levels of IL-8 (P=0.0312). TJ-25 efficacy, on the other hand, was not significantly associated with changes in any hormonal or cytokine levels between the baseline and 12-week visits. However, ΔIL-8 and ΔTNF-α were not significantly correlated with Δstrength and Δfrequency of hot flashes by TJ-25 administration.

Conclusions: Hot flashes were inversely correlated with estradiol and progesterone levels. TJ-25 was more effective in patients with higher TNF-α and IL-8 levels, with no significant change in serum levels caused by the treatment. The suggestive mechanism for the effects of keishibukuryogan is that this drug doesn't suppress the production of IL-8 and TNF-α, but may inhibit some actions of these cytokines.

References

Akaza H . Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment. Pharmacology. 2010; 85(2):110-20. DOI: 10.1159/000274486. View

Moraska A, Atherton P, Szydlo D, Barton D, Stella P, Rowland Jr K . Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB. J Support Oncol. 2010; 8(3):128-32. PMC: 3075822. View

Spetz A, Pettersson B, Varenhorst E, Theodorsson E, Thorell L, Hammar M . Momentary increase in plasma calcitonin gene-related peptide is involved in hot flashes in men treated with castration for carcinoma of the prostate. J Urol. 2001; 166(5):1720-3. View

Keast J, Gleeson R . Androgen receptor immunoreactivity is present in primary sensory neurons of male rats. Neuroreport. 1999; 9(18):4137-40. DOI: 10.1097/00001756-199812210-00025. View

Fujimoto H, Nakanishi H, Miki T, Kubota Y, Takahashi S, Suzuki K . Oncological outcomes of the prostate cancer patients registered in 2004: report from the Cancer Registration Committee of the JUA. Int J Urol. 2011; 18(12):876-81. DOI: 10.1111/j.1442-2042.2011.02895.x. View

Maggio M, Basaria S, Ble A, Lauretani F, Bandinelli S, Ceda G . Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men. J Clin Endocrinol Metab. 2005; 91(1):345-7. DOI: 10.1210/jc.2005-1097. View

Shigehara K, Izumi K, Nakashima K, Kawaguchi S, Nohara T, Kadono Y . Efficacy and safety of keishibukuryogan, a traditional Japanese Kampo medicine, for hot flashes in prostate cancer patients receiving androgen deprivation therapy. Transl Androl Urol. 2021; 9(6):2533-2540. PMC: 7807326. DOI: 10.21037/tau-20-901. View

Kiss M, Kemeny L, Gyulai R, Michel G, Husz S, Kovacs R . Effects of the neuropeptides substance P, calcitonin gene-related peptide and alpha-melanocyte-stimulating hormone on the IL-8/IL-8 receptor system in a cultured human keratinocyte cell line and dermal fibroblasts. Inflammation. 1999; 23(6):557-67. DOI: 10.1023/a:1020294507767. View

Amano T, Imao T, Takemae K . Clinical efficacy of Japanese traditional herbal medicine (Kampo) in patients with late-onset hypogonadism. Aging Male. 2010; 13(3):166-73. DOI: 10.3109/13685530903536684. View

10.

Yoshihisa Y, Furuichi M, Rehman M, Ueda C, Makino T, Shimizu T . The traditional Japanese formula keishibukuryogan inhibits the production of inflammatory cytokines by dermal endothelial cells. Mediators Inflamm. 2011; 2010:804298. PMC: 3021874. DOI: 10.1155/2010/804298. View

11.

Tsujimura A, Nonomura N . Recent topics related to testosterone deficiency syndrome in Japan. Asian J Androl. 2011; 13(4):558-62. PMC: 3739625. DOI: 10.1038/aja.2010.132. View

12.

Wyon Y, Spetz A, Hammar M, Theodorsson E, Varenhorst E . Urinary excretion of calcitonin gene-related peptide in males with hot flushes after castration for carcinoma of the prostate. Scand J Urol Nephrol. 2001; 35(2):92-6. View

13.

Yuzurihara M, Ikarashi Y, Noguchi M, Kase Y, Takeda S, Aburada M . Prevention by 17beta-estradiol and progesterone of calcitonin gene-related peptide-induced elevation of skin temperature in castrated male rats. Urology. 2004; 64(5):1042-7. DOI: 10.1016/j.urology.2004.06.013. View

14.

Nishiyama T, Kanazawa S, Watanabe R, Terunuma M, Takahashi K . Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. Int J Urol. 2004; 11(9):735-41. DOI: 10.1111/j.1442-2042.2004.00896.x. View

15.

Chen J, Shiraki M . Menopausal hot flash and calciotonin gene-related peptide; effect of Keishi-bukuryo-gan, a kampo medicine, related to plasma calciotonin gene-related peptide level. Maturitas. 2003; 45(3):199-204. DOI: 10.1016/s0378-5122(03)00128-2. View

16.

Huang W, Hsin I, Chen D, Chang C, Kor C, Chen T . Circulating interleukin-8 and tumor necrosis factor-α are associated with hot flashes in healthy postmenopausal women. PLoS One. 2017; 12(8):e0184011. PMC: 5573141. DOI: 10.1371/journal.pone.0184011. View

17.

Nakagawa T, Tashiro I, Fujimoto M, Jo M, Sakai S, Oka H . Keishibukuryogan reduces renal injury in the early stage of renal failure in the remnant kidney model. Evid Based Complement Alternat Med. 2009; 2011:914249. PMC: 3137790. DOI: 10.1093/ecam/nep089. View

18.

Langenstroer P, Kramer B, Cutting B, Amling C, Poultan T, Lance R . Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer. J Urol. 2005; 174(2):642-5. DOI: 10.1097/01.ju.0000165570.28635.4b. View

19.

Irani J, Salomon L, Oba R, Bouchard P, Mottet N . Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol. 2009; 11(2):147-54. DOI: 10.1016/S1470-2045(09)70338-9. View

20.

Noguchi M, Ikarashi Y, Yuzurihara M, Kase Y, Chen J, Takeda S . Effects of the Japanese herbal medicine Keishi-bukuryo-gan and 17beta-estradiol on calcitonin gene-related peptide-induced elevation of skin temperature in ovariectomized rats. J Endocrinol. 2003; 176(3):359-66. DOI: 10.1677/joe.0.1760359. View